Introduction: Radiation-associated sarcoma (RAS) is one of the most life-threatening complications associated with the treatment of malignant neoplasms. Because all RAS patients have a history of radiotherapy, there have been no effective treatment options when RAS is not completely resected. Methods: We retrospectively reviewed 20 RAS patients, including 4 unresectable cases treated by carbon ion radiotherapy (CIRT). Results: The primary diseases targeted by radiotherapy included malignant lymphoma (n = 4), cervical cancer (n = 3), pharyngeal cancer (n = 3), breast cancer (n = 2), lung cancer (n = 1), rectal cancer (n = 1), maxillary cancer (n = 1), synovial sarcoma (n = 1), and benign neoplasms (n = 4). The histological diagnoses of RAS included osteosarcoma (n = 8), leiomyosarcoma (n = 3), undifferentiated pleomorphic sarcoma (n = 3), rhabdomyosarcoma (n = 1), angiosarcoma (n = 1), malignant peripheral nerve sheath tumor (n = 1), spindle cell sarcoma NOS (n = 1), and sarcoma not further specified (n = 2). The median survival time from the diagnosis of RAS was 26 months. Eleven patients underwent surgery. Five of these patients achieved a continuous disease free (CDF) status or showed no evidence disease. Four patients underwent CIRT. One of these patients with leiomyosarcoma achieved a CDF status, and the other patient with osteosarcoma achieved a partial response. On the other hand, 2 patients experienced grade 3 toxicities that required surgical treatment. Conclusion: RAS originates from various types of diseases that are treated by radiotherapy and shows diverse pathological features. Complete resection achieves a good prognosis. CIRT can be an effective and feasible option for unresectable RAS.

1.
Allemani
C
,
Weir
HK
,
Carreira
H
,
Harewood
R
,
Spika
D
,
Wang
XS
,
Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)
.
Lancet
.
2015 Mar
;
385
(
9972
):
977
1010
.
2.
Bhakta
N
,
Liu
Q
,
Ness
KK
,
Baassiri
M
,
Eissa
H
,
Yeo
F
,
The cumulative burden of surviving childhood cancer: an initial report from the St. Jude lifetime cohort study (SJLIFE)
.
Lancet
.
2017
;
390
(
10112
):
2569
82
.
3.
Shahrokni
A
,
Wu
AJ
,
Carter
J
,
Lichtman
SM
.
Long-term toxicity of cancer treatment in older patients
.
Clin Geriatr Med
.
2016 Feb
;
32
(
1
):
63
80
. .
4.
Mark
RJ
,
Bailet
JW
,
Poen
J
,
Tran
LM
,
Calcaterra
TC
,
Abemayor
E
,
Postirradiation sarcoma of the head and neck
.
Cancer
.
1993
;
72
(
3
):
887
93
.
5.
Bjerkehagen
B
,
Småstuen
MC
,
Hall
KS
,
Skjeldal
S
,
Smeland
S
,
Fosså
SD
.
Why do patients with radiation-induced sarcomas have a poor sarcoma-related survival?
Br J Cancer
.
2012
;
106
(
2
):
297
306
. .
6.
Gladdy
RA
,
Qin
LX
,
Moraco
N
,
Edgar
MA
,
Antonescu
CR
,
Alektiar
KM
,
Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas?
J Clin Oncol
.
2010
;
28
(
12
):
2064
9
.
7.
Demizu
Y
,
Jin
D
,
Sulaiman
NS
,
Nagano
F
,
Terashima
K
,
Tokumaru
S
,
Particle therapy using protons or carbon ions for unresectable or incompletely resected bone and soft tissue sarcomas of the pelvis
.
Int J Radiat Oncol Biol Phys
.
2017
;
98
(
2
):
367
74
.
8.
Serizawa
I
,
Kagei
K
,
Kamada
T
,
Imai
R
,
Sugahara
S
,
Okada
T
,
Carbon ion radiotherapy for unresectable retroperitoneal sarcomas
.
Int J Radiat Oncol Biol Phys
.
2009
;
75
(
4
):
1105
10
.
9.
Kamada
T
,
Tsujii
H
,
Tsuji
H
,
Yanagi
T
,
Mizoe
J
,
Miyamoto
T
,
Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas
.
J Clin Oncol
.
2002 Nov
;
20
(
22
):
4466
71
.
10.
Matsunobu
A
,
Imai
R
,
Kamada
T
,
Imaizumi
T
,
Tsuji
H
,
Tsujii
H
,
Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk
.
Cancer
.
2012
;
118
(
18
):
4555
63
.
11.
Imai
R
,
Kamada
T
,
Araki
N
,
Abe
S
,
Iwamoto
Y
,
Ozaki
T
,
Carbon ion radiation therapy for unresectable sacral chordoma: an analysis of 188 cases
.
Int J Radiat Oncol Biol Phys
.
2016
;
95
(
1
):
322
7
.
12.
Matsumoto
K
,
Imai
R
,
Kamada
T
,
Maruyama
K
,
Tsuji
H
,
Tsujii
H
,
Impact of carbon ion radiotherapy for primary spinal sarcoma
.
Cancer
.
2013
;
119
(
19
):
3496
503
.
13.
Imai
R
,
Kamada
T
,
Araki
N
,
Abe
S
,
Iwamoto
Y
,
Ozaki
T
,
Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma
.
Cancer Med
.
2018
;
7
(
9
):
4308
14
.
14.
Cahan
WG
,
Woodard
HQ
,
Higinbotham
NL
,
Stewart
FW
,
Coley
BL
.
Sarcoma arising in irradiated bone: report of eleven cases
.
1948
.
Cancer
.
1998
;
82
(
1
):
8
34
.
15.
Kanai
T
,
Endo
M
,
Minohara
S
,
Miyahara
N
,
Koyama-ito
H
,
Tomura
H
,
Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy
.
Int J Radiat Oncol
.
1999 Apr
;
44
(
1
):
201
10
.
16.
Yokoyama
R
,
Beppu
Y
,
Tobisu
KI
,
Moriya
Y
,
Uchiyama
K
,
Kito
M
,
A multidisciplinary approach to the treatment of malignant pelvic bone tumors: results with eight consecutive patients
.
J Orthop Sci
.
2000
;
5
(
5
):
449
56
.
17.
Eilber
F
,
Giuliano
A
,
Eckardt
J
,
Patterson
K
,
Moseley
S
,
Goodnight
J
.
Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial
.
J Clin Oncol
.
1987 Jan
;
5
(
1
):
21
6
. .
18.
Crist
WM
,
Anderson
JR
,
Meza
JL
,
Fryer
C
,
Raney
RB
,
Ruymann
FB
,
Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease
.
J Clin Oncol
.
2001 Jun
;
19
(
12
):
3091
102
.
19.
Masui
F
,
Yokoyama
R
,
Soshi
S
,
Beppu
Y
,
Asanuma
K
,
Fujii
K
.
A malignant peripheral nerve-sheath tumour responding to chemotherapy
.
J Bone Joint Surg Br
.
2004
;
86
(
1
):
113
5
. .
20.
Bray
F
,
Ferlay
J
,
Soerjomataram
I
,
Siegel
RL
,
Torre
LA
,
Jemal
A
.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
.
CA Cancer J Clin
.
2018
;
68
(
00
):
394
424
. .
21.
Cleary
J
,
Gelband
H
,
Wagner
J
.
Cancer: disease control priorities
. 3rd ed.
Dis Control Priorities
;
2015
. p.
1
363
.
22.
Neuhaus
SJ
,
Pinnock
N
,
Giblin
V
,
Fisher
C
,
Thway
K
,
Thomas
JM
,
Treatment and outcome of radiation-induced soft-tissue sarcomas at a specialist institution
.
Eur J Surg Oncol
.
2009 Jun
;
35
(
6
):
654
9
.
23.
Bjerkehagen
B
,
Smeland
S
,
Walberg
L
,
Skjeldal
S
,
Sundby Hall
K
,
Nesland
JM
,
Radiation-induced sarcoma: 25-year experience from the Norwegian radium hospital
.
Acta Oncol
.
2008
;
47
(
8
):
1475
82
.
24.
Lagrange
JL
,
Ramaioli
A
,
Chateau
MC
,
Marchal
C
,
Resbeut
M
,
Richaud
P
,
Sarcoma after radiation therapy: retrospective multiinstitutional study of 80 histologically confirmed cases
.
Radiology
.
2000 Jul
;
216
(
1
):
197
205
.
25.
Schulz-Ertner
D
,
Jäkel
O
,
Schlegel
W
.
Radiation therapy with charged particles
.
Semin Radiat Oncol
.
2006
;
16
(
4
):
249
59
. .
26.
Suzuki
M
,
Kase
Y
,
Yamaguchi
H
,
Kanai
T
,
Ando
K
.
Relative biological effectiveness for cell-killing effect on various human cell lines irradiated with heavy-ion medical accelerator in Chiba (HIMAC) carbon-ion beams
.
Int J Radiat Oncol Biol Phys
.
2000
;
48
(
1
):
241
50
. .
27.
Barcellini
A
,
Vitolo
V
,
Cobianchi
L
,
Peloso
A
,
Vanoli
A
,
Mirandola
A
,
Re-irradiation with carbon ion radiotherapy for pelvic rectal cancer recurrences in patients previously irradiated to the pelvis
.
In Vivo
.
2020
;
34
(
3
):
1547
53
.
28.
Hogan
NM
,
Kerin
MJ
,
Joyce
MR
.
Gastrointestinal complications of pelvic radiotherapy: medical and surgical management strategies
.
Curr Probl Surg
.
2013
;
50
(
9
):
395
407
. .
29.
Held
T
,
Windisch
P
,
Akbaba
S
,
Lang
K
,
El Shafie
R
,
Bernhardt
D
,
Carbon ion reirradiation for recurrent head and neck cancer: a single-institutional experience
.
Int J Radiat Oncol Biol Phys
.
2019
;
105
(
4
):
803
11
.
30.
Held
T
,
Harrabi
SB
,
Lang
K
,
Akbaba
S
,
Windisch
P
,
Bernhardt
D
,
Dose-limiting organs at risk in carbon ion re-irradiation of head and neck malignancies: an individual risk-benefit tradeoff
.
Cancers
.
2019
;
11
(
12
):
4
13
.
31.
Kumar
G
,
Yadav
V
,
Singh
P
,
Bhowmik
KT
.
Radiation-induced malignancies making radiotherapy a “ two-edged sword ”: a review of literature
.
World J Oncol
.
2017
;
8
(
1
):
1
6
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.